Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07159841 · ClinicalTrials.gov registry record · Phase 2
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
A Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 18
- Study locations
NCT07159841: Recruiting Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, sponsored by Crinetics Pharmaceuticals.
NCT07159841 is a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 153 participants, above the 83-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (84% higher). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07159841, a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atumelnant
Study Locations (18)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Instituto Médico Especializado (IME) - Buenos Aires
- Hopital Kremlin-Bicétre - APHP Paris Saclay - Le Kremlin-Bicêtre
- Hopital Robert Debre - Paris
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
New Jersey
- Rutgers Robert Wood Johnson Medical School - New Brunswick
Texas
- Cook Children's Health Care System - Fort Worth
Virginia
- University of Virginia Health System - Charlottesville
New South Wales
- Institute of Endocrinology of Diabetes, The Children's Hospital at Westmead - Westmead
Queensland
- Queensland Children's Hospital - South Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
What NCT07159841 shows while recruiting
NCT07159841 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (84% higher).
The record links to 2 conditions, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07159841 lists 18 locations in 15 states (Other, Michigan, Minnesota).
Frequently Asked Questions
What is clinical trial NCT07159841 about?
NCT07159841 is a clinical study titled "A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
What is the current status of trial NCT07159841?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2026-01-22. Estimated completion is 2030-03.
What conditions does trial NCT07159841 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia.
What interventions are being tested in trial NCT07159841?
The interventions under investigation include: Placebo (DRUG), Atumelnant (DRUG).
Who is sponsoring clinical trial NCT07159841?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07159841 being conducted?
This trial has 18 study locations across Michigan, Minnesota, New Jersey, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07159841's enrollment target sits among peer trials
153 2nd of 8 the highest of 8 other Congenital Adrenal Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Adrenal Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
RECRUITING · Phase 2
-
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
COMPLETED · Phase 2
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
ACTIVE NOT RECRUITING · Phase 1
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI